CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.
The causal relationships among CD4 cell depletion, HIV replication, and immune activation are not well understood. HIV-2 infection, "nature's experiment" with inherently attenuated HIV disease, provides additional insights into this issue. We report the finding that in HIV-2 and HIV-1 patients with a comparable degree of CD4 depletion the imbalance in the relative sizes of the naive and memory T cell populations and the up-regulation of CD4 and CD8 cell activation markers (HLA-DR, CD38, CD69, Fas molecules) are similar, even though the viral load in the plasma of HIV-2-infected patients is two orders of magnitude lower than in HIV-1 patients and HIV-2 patients are known to have slower rates of CD4 T cell decline and a better clinical prognosis. Moreover, we found a similar increase in the frequency of cycling CD4 T cells (Ki67+), which was in strong correlation with the expression of activation markers. Finally, the level of T cell anergy, as assessed by the proliferative responses to CD3 stimulation and to a panel of microbial Ags, proved to be comparable in HIV-1 and HIV-2 patients with a similar degree of CD4 depletion despite large differences in viral load. Our data are consistent with a direct causal relationship between immune activation and CD4 cell depletion in HIV disease and an only indirect relation of these parameters to the virus replication rate. Invoking the concept of proximal immune activation and virus transmission, which links efficient transmission of virus to local cell activation and proliferation in response to Ags and inflammation, we propose an integrative interpretation of the data and suggest that strongly elevated immune activation induces CD4 cell depletion and not vice versa, with potential implications for the choice of treatment strategies.
Sousa
Ana E
AE
Clinical Immunology Unit/Institute of Molecular Medicine, Faculty of Medicine of Lisbon, Lisbon, Portugal. anaesousa@netcabo.pt
Carneiro
Jorge
J
Meier-Schellersheim
Martin
M
Grossman
Zvi
Z
Victorino
Rui M M
RM
D015415:Biomarkers / Q000097:blood; D017252:CD3 Complex / Q000494:pharmacology; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002453:Cell Cycle / Q000276:immunology; D002478:Cells, Cultured; D015658:HIV Infections / Q000276:immunology* / Q000473:pathology / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory; D016130:Immunophenotyping; D007399:Interphase / Q000276:immunology; D008213:Lymphocyte Activation; D008231:Lymphopenia / Q000276:immunology* / Q000473:pathology / Q000821:virology; D008934:Mitogens / Q000494:pharmacology; D015854:Up-Regulation / Q000276:immunology; D019562:Viral Load; D019014:fas Receptor / Q000096:biosynthesis
D015415:Biomarkers; D017252:CD3 Complex; D008934:Mitogens; D019014:fas Receptor